Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.99 USD | -0.99% | +0.95% | -21.88% |
Apr. 22 | Citigroup Starts Privia Health Group With Buy Rating, $25 Price Target | MT |
Mar. 19 | Canaccord Genuity Adjusts Privia Health Group Price Target to $37 From $41, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 76.39 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.88% | 2.16B | C+ | ||
-14.73% | 85.42B | B- | ||
+16.05% | 84.38B | C+ | ||
+10.92% | 29.39B | C+ | ||
-12.73% | 17.49B | B | ||
-3.17% | 16.44B | A- | ||
-1.78% | 15.28B | A- | ||
-0.45% | 12.22B | A- | ||
-31.23% | 11.98B | - | - | |
-2.51% | 11.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PRVA Stock
- Ratings Privia Health Group, Inc.